Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)

NCT06198907 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Non-Small-Cell Lung Cancer

Interventions

DRUG: Golidocitinib
DRUG: Sintilimab
DRUG: platinum doublet chemotherapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]